Key Market Indicators
Norwegian pharmaceutical research and development expenditure is projected to decline to approximately $38 million PPP by 2028, down from around $39 million PPP in 2023. This represents an average annual decrease of 0.3%. Since 2013, Norway's investment in pharmaceutical R&D has seen a consistent annual decline of 2.8%. In 2023, Norway ranked 15th globally in R&D spending. Mexico surpassed Norway with an expenditure of approximately $39 million PPP. Leading the global rankings were China, Germany, and South Korea, holding the second, third, and fourth positions, respectively.
